000 | 01976 a2200577 4500 | ||
---|---|---|---|
005 | 20250515221832.0 | ||
264 | 0 | _c20100504 | |
008 | 201005s 0 0 eng d | ||
022 | _a1873-4456 | ||
024 | 7 |
_a10.1016/j.cancergencyto.2010.01.018 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aOshikawa, Gaku | |
245 | 0 | 0 |
_aClonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation. _h[electronic resource] |
260 |
_bCancer genetics and cytogenetics _cMay 2010 |
||
300 |
_a56-61 p. _bdigital |
||
500 | _aPublication Type: Case Reports; Journal Article | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 | _aBase Sequence |
650 | 0 | 4 | _aBenzamides |
650 | 0 | 4 |
_aBone Marrow _xpathology |
650 | 0 | 4 |
_aCell Transformation, Neoplastic _xgenetics |
650 | 0 | 4 | _aClone Cells |
650 | 0 | 4 | _aDNA Mutational Analysis |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xgenetics |
650 | 0 | 4 | _aGene Expression Regulation, Leukemic |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImatinib Mesylate |
650 | 0 | 4 | _aIn Situ Hybridization, Fluorescence |
650 | 0 | 4 | _aKaryotyping |
650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMolecular Sequence Data |
650 | 0 | 4 | _aPhiladelphia Chromosome |
650 | 0 | 4 |
_aPiperazines _xtherapeutic use |
650 | 0 | 4 | _aPolyploidy |
650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
650 | 0 | 4 |
_aRNA, Neoplasm _xanalysis |
650 | 0 | 4 | _aTime Factors |
700 | 1 | _aKurosu, Tetsuya | |
700 | 1 | _aArai, Ayako | |
700 | 1 | _aMurakami, Naomi | |
700 | 1 | _aMiura, Osamu | |
773 | 0 |
_tCancer genetics and cytogenetics _gvol. 199 _gno. 1 _gp. 56-61 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.cancergencyto.2010.01.018 _zAvailable from publisher's website |
999 |
_c19775135 _d19775135 |